Strong early data for Sylentis' ocular pain RNAi drug candidate
Sylentis, an RNAi specialist firm owned by Spain's Zeltia Group, presented strong data on its compounds for ophthalmic indications at the 2009 Congress of the Association for Research in Vision and Ophthalmology, in Fort Lauderdale, Florida. According to the firm, pre-treatment with SYL040003 and SYL040003 prevents the intraocular pressure increase induced by an ocular hypertension model. The prophylactic effect of these compounds was higher than the previously-described effect in this model for drugs currently used for the treatment of the condition. In addition, a product for ocular pain associated with dry-eye syndrome showed greater analgesic effect than the reference standard analgesic capsazepine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze